These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31353426)

  • 41. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
    Singh AK; Jatwa R; Purohit A; Ram H
    J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New therapeutic approaches in type 2 diabetes.
    Scheen AJ
    Acta Clin Belg; 2008; 63(6):402-7. PubMed ID: 19170358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.
    McGill JB
    Curr Diabetes Rev; 2012 Jul; 8(4):257-67. PubMed ID: 22515702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of Inpatient Hyperglycemia and Diabetes in Older Adults.
    Davis GM; DeCarlo K; Wallia A; Umpierrez GE; Pasquel FJ
    Clin Geriatr Med; 2020 Aug; 36(3):491-511. PubMed ID: 32586477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
    Freeman JS
    J Am Osteopath Assoc; 2010 Sep; 110(9):528-37. PubMed ID: 20876838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
    Galindo RJ; Fried M; Breen T; Tamler R
    Endocr Pract; 2016 Apr; 22(4):454-65. PubMed ID: 26720253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices.
    Galindo RJ; Dhatariya K; Gomez-Peralta F; Umpierrez GE
    Curr Diab Rep; 2022 Jun; 22(6):237-246. PubMed ID: 35507117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients.
    Gracia-Ramos AE; Carretero-Gómez J; Mendez CE; Carrasco-Sánchez FJ
    Curr Med Res Opin; 2022 Jan; 38(1):43-53. PubMed ID: 34694181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.
    Gallwitz B
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S322-5. PubMed ID: 19875573
    [No Abstract]   [Full Text] [Related]  

  • 59. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!
    Schwartz S; DeFronzo RA
    Diabetes Care; 2013 Jul; 36(7):2107-11. PubMed ID: 23801800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implementation of subcutaneous insulin protocol for non-critically ill hospitalized patients in andalusian tertiary care hospitals.
    Martínez-Brocca MA; Morales C; Rodríguez-Ortega P; González-Aguilera B; Montes C; Colomo N; Piédrola G; Méndez-Muros M; Serrano I; Ruiz de Adana MS; Moreno A; Fernández I; Aguilar M; Acosta D; Palomares R
    Endocrinol Nutr; 2015 Feb; 62(2):64-71. PubMed ID: 25467634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.